Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

  • There is currently no data for NSCI

Netscientific Appoints Ian Postlethwaite as CFO

5 Apr 2016 07:00

RNS Number : 1367U
NetScientific PLC
05 April 2016
 

 

 

("NetScientific" or the "Company" or the "Group")

 

Netscientific Appoints Ian Postlethwaite as Chief Financial Officer

 

London, UK - 5th April 2016 - NetScientific plc ("NetScientific", AIM:NSCI), the transatlantic biomedical and healthcare technology group, is pleased to announce that Ian Postlethwaite has accepted the role as Chief Financial Officer. Ian will join the Company and the Board as soon as his current employer has appointed a suitable successor and allowed time for an orderly handover. A subsequent announcement detailing Ian's start date will be made in due course.

 

Ian Postlethwaite is currently the Finance Director and Company Secretary of Allergy Therapeutics plc, where he has held the roles since May 2002. Ian previously held senior finance and executive management positions with AFS (1997-2002), Ericsson (1994-1997) and Phillips Electronics (1989-1994). Ian is a Fellow of the Chartered Association of Certified Accountants. He graduated from Aston University in 1985 with a BSc (Hons) in Geological Sciences.

 

Commenting on the appointment, Sir Richard Sykes, Chairman of NetScientific, said: "I am delighted to welcome Ian to NetScientific as our new Chief Financial Officer. His wealth of experience at Board level in raising capital for listed growth companies with international operations in the healthcare sector will be a huge asset to the Company as we move forward with our new focus on digital health, diagnostics and therapeutics.

 

"We very much look forward to working with Ian as he becomes a pivotal member of our team. Until he commences Mark Nanovich will continue in his role as Interim CFO, and we would like to thank Mark for his continued contribution in helping to support the business during our recent period of transition."

 

Ian Postlethwaite commented: "I am excited to be joining NetScientific - this is a rapidly progressing group with an exciting portfolio of high-quality assets focused on dynamic new areas in healthcare. I look forward to working with the team to build value."

 

 

Ian David Postlethwaite, aged 53 years, has been a director of the following companies during the five years preceding the date of this announcement:

 Current directorships

Past Directorships

Allergy Therapeutics plc

Allergy Therapeutics Developments

Allergy Therapeutics (Holdings) Limited

Limited

Bencard Allergie GmbH

 

Allergy Therapeutics Italia s.r.l.

 

Allergy Therapeutics Iberia S.L.

 

Sussex Port Forwarding Limited

Shoreham Port Developments And Investments Limited

Teomed AG

 

 

 

There is no further information to be disclosed under Schedule Two paragraph (g) of the AIM Rules for Companies.

 

- Ends -

 

 

For more information, please contact:

 

NetScientific

François R. Martelet, M.D., CEO

Mark Nanovich, Interim CFO

 

Tel: +44 (0)20 3514 1800

Investec (NOMAD and broker)

Gary Clarence / Daniel Adams

Tel: +44 (0)20 7597 4000

 

Consilium Strategic Communications

Mary-Jane Elliott / Chris Gardner / Jessica Hodgson / Chris Welsh / Laura Thornton

 

Tel: +44 (0)20 3709 5700

netscientific@consilium-comms.com

 

 

About NetScientific Plc

 

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment. For more information, please visit the website at www.netscientific.net.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOALFFEISRISIIR
Date   Source Headline
24th May 20177:00 amRNSVortex Initiates Clinical Research Studies
10th May 20177:00 amRNSProAxsis announces additional IP
5th May 20177:00 amRNSProAxsis Presents New Data at Major US Conference
24th Apr 20177:00 amRNSBTG purchases Wanda's shares in Oncoverse
3rd Apr 20177:00 amRNSFull Year Results for the year ended 31 Dec 2016
31st Mar 20177:00 amRNSVortex Biosciences Announces Publications
27th Mar 20177:00 amRNSNotice of Preliminary Results
22nd Feb 20177:00 amRNSVortex Biosciences Launches VTX-1 Liquid Biopsy
15th Feb 20177:00 amRNSVortex Biosciences' CSO Wins SLAS Innovation Award
9th Feb 20177:00 amRNSVortex Biosciences' CSO Finalist for SLAS Award
30th Jan 20177:00 amRNSGrant of Options to Directors
20th Dec 20167:00 amRNSNew CEO appointed to Wanda
16th Dec 20167:00 amRNSExecuted Warrants
18th Nov 20167:00 amRNSNetscientific: Vortex Biosciences Analysis Data
3rd Nov 20164:34 pmRNSVortex Gains CE Mark and FDA Class 1 Registration
26th Oct 201612:30 pmRNSVortex Biosciences Appoints Non-Executive Director
30th Sep 20167:00 amRNSProAxsis Gains CE Mark for its Respiratory Test
27th Sep 20167:00 amRNSNetScientific Interim Results
23rd Sep 20167:00 amRNSWanda Technology Selected by 24Hr HomeCare
12th Sep 20167:00 amRNSGlycotest strengthens IP portfolio
8th Sep 20167:00 amRNSWanda Appoints Digital Health Non-Exec Director
6th Sep 20167:00 amRNSNotice of Interim Results
19th Aug 20167:00 amRNSWanda Launches First Consumer App
18th Aug 20167:06 amRNSVortex Biosciences Appoints Experts to New SAB
3rd Aug 20167:00 amRNSVortex Licenses Patents From Harvard University
28th Jul 20167:00 amRNSChange of Adviser
27th Jul 20167:00 amRNSWanda Appoints Medical Director
22nd Jul 20167:00 amRNSA to Z Home Health Care selects Wanda technologies
27th Jun 20167:00 amRNSGrant of Options to Director
15th Jun 20162:13 pmRNSResult of AGM
14th Jun 20167:00 amRNSVortex Biosciences appoints Chairman of SAB
14th Jun 20167:00 amRNSNetScientific hosts Capital Markets Day
10th Jun 20167:30 amRNSConfirmed Start Date for Ian Postlethwaite as CFO
7th Jun 20167:00 amRNSPortfolio PDS Biotechnology presents at BIO 2016
23rd May 20169:00 amRNSNotice of AGM
18th Apr 20167:00 amRNSNetScientific's Vortex presents data at AACR
13th Apr 20167:00 amRNSPDS Biotechnology Reports Positive Phase 1 Results
7th Apr 20167:00 amRNSAnnual Financial Report
5th Apr 20167:00 amRNSNetscientific Appoints Ian Postlethwaite as CFO
30th Mar 20167:00 amRNSProAxsis Forms Scientific Advisory Board
24th Mar 20167:00 amRNSNotice of Results
16th Mar 20167:00 amRNSWanda Forms Scientific Advisory Board
7th Mar 20162:00 pmRNSAdoption of reduced disclosure framework
1st Mar 20161:00 pmRNSVortex co-founder receives US Presidential award
29th Feb 20167:00 amRNSWanda and Dignity Health launch OncoVerse platform
17th Feb 20167:00 amRNSNetScientific appoints Prof. Stephen Smith as NED
9th Feb 201611:05 amRNSPDS Biotechnology partners with NCI
8th Feb 20163:14 pmRNSGrant of Options to Director
26th Jan 20167:00 amRNSDirectorate Change
20th Jan 201611:09 amRNSPDS Biotechnology adds drug development executives

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.